Summary of the on-trial sample swap between Leeds and Cardiff, run in August 2016
| Sample ID | Cardiff pyrosequencing (VAF) | Leeds pyrosequencing (VAF) | Leeds NGS (VAF) |
| Sample 1 | KRAS c.35G>T (36%) | KRAS c.35G>T (34%) | KRAS c.35G>T (28%) TP53 c.215C>G (41%) |
| Sample 2 | BRAF c.1799T>A (22%) | BRAF c.1799T>A (29%) | BRAF c.1799T>A (21%) TP53 c.215C>G (72%) TP53 c.796G>C (25%) |
| Sample 3 | BRAF c.1799T>A (15%) | BRAF c.1799T>A (22%) | BRAF c.1799T>A (14%) TP53 c.215C>G (64%) TP53 c.524G>A (16%) |
| Sample ID | Leeds pyrosequencing (VAF) | Cardiff pyrosequencing (VAF) | Cardiff NGS (VAF) |
| Sample 4 | BRAF c.1799T>A (52%) | BRAF c.1799T>A (50%) | BRAF c.1799T>A (50%) TP53 c.844C>T (68%) |
| Sample 5 | KRAS c.35G>A (42%) PIK3CA c.1633G>A (51%) | KRAS c.35G>A (55%) PIK3CA c.1633G>A (41%) | KRAS c.35G>A (36%) PIK3CA c.1633G>A (50%) |
| Sample 6 | KRAS c.436G>A (72%) | KRAS c.436G>A (100%) | KRAS c.436G>A (72%) TP53 c.832C>T (66%) |
The TP53 mutations detected by NGS are outside the scope of the pyrosequencing assay panel, so not detected by the latter assay.
NGS, next-generation sequencing; VAF, variant allele frequency.